Manju Dawkins, MD’s Post

📍Novo Nordisk diabetes drug Ozempic, known chemically as semaglutide, has shown promising results in a late-stage trial. 📍The drug slowed the worsening of kidney problems and reduced the risk of kidney failure, heart issues, stroke, and death in patients with type 2 diabetes. 📍The trial, which involved weekly 1-milligram injections, found that Ozempic cut the combined risk of these complications by 24% over 3.4 years compared to a placebo. #novonordisk #diabetes #healthmanagement #ozempic #semaglutide #clinicaltrails

Combining Aspirin and Vascepa: Is There a Recommended Dosage?Aspirin and Vascepa are two medications commonly prescribed to patients with cardiovascular conditions. While they are often used together, it's essential to understand the recommended dosage and potential interactions between the two drugs. In this article, we'll delve into the world of aspirin and Vascepa, exploring their individual benefits,... https://lnkd.in/emnfRzgq

Combining Aspirin and Vascepa: Is There a Recommended Dosage?Aspirin and Vascepa are two medications commonly prescribed to patients with cardiovascular conditions. While they are often used together, it's essential to understand the recommended dosage and potential interactions between the two drugs. In this article, we'll delve into the world of aspirin and Vascepa, exploring their individual benefits,... https://lnkd.in/eaqkN6rp

What is APROCITENTAN? Aprocitentan (brand name: Tryvio) is a medication belonging to a new drug class called endothelin receptor antagonists (ERAs). It's the first ERA approved by the FDA (in March 2024) specifically for treating high blood pressure (arterial hypertension). How Does it Work? Aprocitentan works by blocking the effects of endothelin, a substance in the body that can narrow blood vessels. By blocking endothelin, Aprocitentan helps blood vessels relax and widen, leading to lower blood pressure. How is it Used? The recommended dosage for Aprocitentan is 12.5 milligrams (mg) taken by mouth (PO) once daily (OD). It's important to follow your doctor's specific instructions for taking Aprocitentan. Why is it Unique? Previously available medications for high blood pressure target different mechanisms. Aprocitentan offers a new approach for patients who might not respond adequately to other medications. Important Considerations: Aprocitentan is typically used in combination with other blood pressure medications, not as a first-line treatment. It's relatively new, so long-term effects are still being studied. As with any medication, there can be side effects. Talk to your doctor about potential benefits and risks of Aprocitentan for your specific situation.

OTC proton pump inhibitors (PPIs), highlighting their dual role in providing convenient relief for acid-related issues while also posing risks of overuse and potential long-term side effects. This underscores the importance of balancing accessibility with proper usage guidance. As healthcare professionals, it's crucial to promote informed decisions through patient education to maximize benefits and minimize risks. https://lnkd.in/gtg2rf3T

Ozempic Gains FDA Approval for Chronic Kidney Disease Treatment in Diabetics : The FDA has approved Novo Nordisk’s Ozempic to treat chronic kidney disease in people with Type 2 diabetes, expanding its use beyond diabetes management. A major study showed Ozempic can slow kidney decline, lower the risk of heart-related deaths, and reduce severe kidney complications by 24%. This approval highlights the broader health benefits of GLP-1 drugs like Ozempic, which are already used for diabetes and weight loss, while Novo Nordisk faces growing competition and ongoing Medicare drug price negotiations. Read more: https://lnkd.in/d8hQYpbp #fdaapproval #fda #ozempic #nephrology #medicalresearch #clinicalresearch #medicalupdate #medicalupdates #medicalnews #pharmaupdate #pharmaupdates #pharmanews #healthcareupdate #healthcareupdates #healthcarenews #hcp #scientificupdate #clinicalguideline #clinicalguidelines #medicalguideline #medicalguidelines #carbonbrandsolutions

Wegovy—Novo Nordisk, is now the first weight-loss medication to also win FDA approval as an intervention for lowering cardiovascular (CV) risk in adults with obesity or overweight. The findings showed that Wegovy reduced the risk of stroke, heart attack, and other CV problems by 20% in this population. Semaglutide, which is also the active ingredient in Novo's diabetes drug Ozempic, works by delaying emptying of the stomach — which has the effect of suppressed appetite in users. While FDA's decision raises hope that more insurers will cover Wegovy for more patients, effectively bringing production up to meet demand and driving prices down are still challenges. https://lnkd.in/ePvvr8-H

🎉 FDA greenlights Attruby™ (acoramidis) for treating transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). This oral treatment aims to reduce cardiovascular death & hospitalization. Expected launch soon with an annual cost of $244K. More details on its promising impact! https://lnkd.in/esKEc3s3 #HeartHealth #ATTRCM

Very exciting update on ATAI Life Sciences AG's and Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a patent-protected, intravenous formulation of psilocin, which is the active moiety in the body when psilocybin is administered orally. As such, I view ELE-101 as a relatively de-risked asset for its stage of development, as it leverages the robust proof-of-concept data that has been established with psilocybin across multiple trials. Especially, it has the potential to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter (!) treatment paradigm of less than 2 hours. So much larger TAM/business upside. #psychedelics #investing #future